SG11202001535RA - Method of targeting exosomes - Google Patents
Method of targeting exosomesInfo
- Publication number
- SG11202001535RA SG11202001535RA SG11202001535RA SG11202001535RA SG11202001535RA SG 11202001535R A SG11202001535R A SG 11202001535RA SG 11202001535R A SG11202001535R A SG 11202001535RA SG 11202001535R A SG11202001535R A SG 11202001535RA SG 11202001535R A SG11202001535R A SG 11202001535RA
- Authority
- SG
- Singapore
- Prior art keywords
- targeting exosomes
- exosomes
- targeting
- Prior art date
Links
- 210000001808 exosome Anatomy 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4866—Protein C (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0695—Stem cells; Progenitor cells; Precursor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
- C12N5/0631—Mammary cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762554530P | 2017-09-05 | 2017-09-05 | |
US201762554533P | 2017-09-05 | 2017-09-05 | |
US201762569403P | 2017-10-06 | 2017-10-06 | |
US201762569411P | 2017-10-06 | 2017-10-06 | |
US201762584565P | 2017-11-10 | 2017-11-10 | |
US201762593014P | 2017-11-30 | 2017-11-30 | |
PCT/US2018/049619 WO2019050998A1 (en) | 2017-09-05 | 2018-09-05 | Method of targeting exosomes |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202001535RA true SG11202001535RA (en) | 2020-03-30 |
Family
ID=63714024
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202001536PA SG11202001536PA (en) | 2017-09-05 | 2018-09-05 | Delivery of payloads to stem cells |
SG11202001535RA SG11202001535RA (en) | 2017-09-05 | 2018-09-05 | Method of targeting exosomes |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202001536PA SG11202001536PA (en) | 2017-09-05 | 2018-09-05 | Delivery of payloads to stem cells |
Country Status (14)
Country | Link |
---|---|
US (3) | US20200407421A1 (en) |
EP (3) | EP3679129A1 (en) |
JP (4) | JP2020533976A (en) |
KR (2) | KR20200050975A (en) |
CN (2) | CN111065733A (en) |
AU (2) | AU2018330427A1 (en) |
BR (2) | BR112020003945A2 (en) |
CA (2) | CA3074678A1 (en) |
IL (2) | IL272908A (en) |
MX (2) | MX2020002250A (en) |
PE (2) | PE20201462A1 (en) |
SG (2) | SG11202001536PA (en) |
WO (3) | WO2019051002A1 (en) |
ZA (2) | ZA202000650B (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3524617T3 (en) | 2013-03-15 | 2023-05-15 | Gladiator Biosciences Inc | GLA DOMAINS AS THERAPEUTIC AGENTS |
GB2578394A (en) | 2017-08-07 | 2020-05-06 | Univ California | Platform for generating safe cell therapeutics |
PE20201462A1 (en) | 2017-09-05 | 2020-12-17 | Gladiator Biosciences Inc | EXOSOME ADDRESSING METHOD |
CN110036976B (en) * | 2019-05-08 | 2021-12-07 | 华南农业大学 | Method for blocking vertical transmission of avian leukosis virus and application thereof |
CN110423777A (en) * | 2019-07-23 | 2019-11-08 | 河南科技大学 | Unstressed configuration dye marker excretion body and preparation method thereof |
CN110711249B (en) * | 2019-09-19 | 2020-10-27 | 北京化工大学 | Preparation method of lysosome membrane-coated nanoparticles |
KR102547446B1 (en) * | 2019-11-29 | 2023-06-26 | 서울대학교산학협력단 | Label-free Polydiacetylene Liposome-based Method for Detection of Exosomes |
CN111803646B (en) * | 2020-06-04 | 2022-07-05 | 苏州大学 | Solid tumor combination treatment composition |
US20210393536A1 (en) * | 2020-06-23 | 2021-12-23 | Board Of Regents, The University Of Texas System | Methods and compositions related to extracellular vesicles |
KR102659285B1 (en) * | 2020-08-11 | 2024-04-22 | 경북대학교 산학협력단 | Peptides that selectively bind to tumor-derived exosomes and use thereof |
CN112516110B (en) * | 2020-10-13 | 2022-05-13 | 北京化工大学 | Method for coating nano enzyme on cell membrane |
CN112285195B (en) * | 2020-10-27 | 2021-08-10 | 江南大学 | Characteristic glycoprotein marker of milk exosome and characteristic marker separation method of milk exosome |
KR102285160B1 (en) * | 2020-12-24 | 2021-08-03 | 주식회사 타임바이오 | Pharmaceutical composition for the prevention and treatment of dermatitis using progenitor cell derived multifunctional exosomes |
CN114940967B (en) * | 2022-05-09 | 2024-05-31 | 中山大学 | Breast milk extracellular vesicles and application thereof in preparation of bone repair materials |
CN116421738B (en) * | 2023-02-28 | 2024-03-19 | 中国医科大学附属第一医院 | Oncolytic virus for capturing antigen and pharmaceutical composition, preparation and application thereof |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
US5475085A (en) | 1991-02-07 | 1995-12-12 | Molecumetics, Ltd. | Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same |
JPH06505486A (en) | 1991-02-07 | 1994-06-23 | モレキュメティクス,リミティド | Conformationally restricted mimetics of β-turns and β-bulges and peptides containing them |
GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
US5329028A (en) | 1992-08-05 | 1994-07-12 | Genentech, Inc. | Carbohydrate-directed cross-linking reagents |
NZ255256A (en) | 1992-08-27 | 1997-02-24 | Deakin Res Ltd | Synthetic peptide antigen analogues with retro, inverso or retro-inverso modification, their use and antibodies against them |
US5581476A (en) | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
US5446128A (en) | 1993-06-18 | 1995-08-29 | The Board Of Trustees Of The University Of Illinois | Alpha-helix mimetics and methods relating thereto |
EP0706564A1 (en) | 1993-06-30 | 1996-04-17 | Rijksuniversiteit Leiden | Protein s deletion variants deficient in c4bp binding activity, but having apc cofactor activity, compositions and therapeutic methods |
US5597457A (en) | 1995-01-23 | 1997-01-28 | The Regents Of The University Of California | System and method for forming synthetic protein crystals to determine the conformational structure by crystallography |
US5840833A (en) | 1995-10-27 | 1998-11-24 | Molecumetics, Ltd | Alpha-helix mimetics and methods relating thereto |
US5929237A (en) | 1995-10-27 | 1999-07-27 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
WO1998029453A1 (en) | 1996-12-27 | 1998-07-09 | Mochida Pharmaceutical Co., Ltd. | Cell membrane-directed drugs |
US6093573A (en) | 1997-06-20 | 2000-07-25 | Xoma | Three-dimensional structure of bactericidal/permeability-increasing protein (BPI) |
ATE230614T1 (en) | 1998-07-13 | 2003-01-15 | Univ Texas | CANCER TREATMENT WITH AMINOPHOSPHOLIPIDE-BINDING THERAPEUTIC CONJUGATES |
AU5483699A (en) | 1998-08-13 | 2000-03-06 | American Home Products Corporation | Crystal structure of escherichia coli gdp-fucose synthetase and methods of its use |
NZ510230A (en) | 1998-08-25 | 2004-01-30 | Scripps Research Inst | Predicting protein function by electronic comparison of functional site descriptors |
US6801860B1 (en) | 1999-02-15 | 2004-10-05 | Genetics Institute, Llc | Crystal structure of cPLA2 and methods of identifying agonists and antagonists using same |
US20040001827A1 (en) | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
JP2002003407A (en) | 2000-06-20 | 2002-01-09 | Medei Sci Puraningu:Kk | Hydroxyapatite calciophilic drug carrier |
WO2003017032A2 (en) | 2001-08-14 | 2003-02-27 | Dana-Farber Cancer Institute, Inc. | Computer-based methods of designing molecules |
US7807174B2 (en) | 2002-11-22 | 2010-10-05 | Nexbio, Inc. | Class of therapeutic protein based molecules |
NZ544728A (en) | 2003-06-19 | 2009-04-30 | Bayer Healthcare Llc | Factor VII or VIIa Gla domain variants |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
WO2005003169A2 (en) | 2003-07-01 | 2005-01-13 | Celltech R & D Limited | Modified antibody fab fragments |
GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
CN1863545A (en) * | 2003-08-15 | 2006-11-15 | 伊利诺斯大学理事会 | Cytotoxic factors for modulating cell death |
WO2005079766A2 (en) | 2004-02-20 | 2005-09-01 | Novo Nordisk A/S | Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds |
GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
RU2448157C2 (en) | 2004-05-26 | 2012-04-20 | Псиоксус Терапьютикс Лимитед | Chimeric adenoviruses applicable for treating malignant growth |
US7511016B2 (en) | 2004-07-07 | 2009-03-31 | Mosamedix B.V. | Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof |
DE602005021509D1 (en) | 2004-08-17 | 2010-07-08 | Csl Behring Gmbh | MODIFIED VITAMIN K-DEPENDENT POLYPEPTIDE |
CN104277117A (en) * | 2005-01-24 | 2015-01-14 | 得克萨斯大学体系董事会 | Constructs binding to phosphatidylserine and their use in disease treatment |
KR100987547B1 (en) * | 2006-06-01 | 2010-10-12 | 가톨릭대학교 산학협력단 | A composition and a kit for detecting early apoptosis in frozen umbilical cord blood and a method therefor |
CA2673520A1 (en) | 2006-12-22 | 2008-07-03 | Bayer Schering Pharma Aktiengesellschaft | Generation of oncolytic adenoviruses and uses thereof |
JP5130580B2 (en) | 2007-01-17 | 2013-01-30 | 独立行政法人放射線医学総合研究所 | Detection marker for low-dose exposure in stem cells, and method for estimating or detecting low-dose exposure level in stem cells using the marker |
US20100166729A9 (en) | 2007-04-13 | 2010-07-01 | Madison Edwin L | Modified factor VII polypeptides and uses thereof |
KR100968839B1 (en) | 2008-02-25 | 2010-07-09 | 경북대학교 산학협력단 | Polypeptide binding phosphatidylserine specifically and use thereof |
TWI538916B (en) * | 2008-04-11 | 2016-06-21 | 介控生化科技公司 | Factor vii polypeptides that are modified and uses thereof |
WO2010006136A2 (en) * | 2008-07-09 | 2010-01-14 | Mayo Foundation For Medical Education And Research | Adenovirus targeting |
US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
PE20110598A1 (en) | 2008-10-02 | 2011-08-31 | Respivert Ltd | INHIBITORS OF MITOGEN P38 ACTIVATED PROTEIN KINASE ENZYMES |
US8283167B2 (en) | 2009-02-11 | 2012-10-09 | Clear Vascular Inc. | Preparation of annexin derivatives |
RU2563231C2 (en) | 2009-06-25 | 2015-09-20 | Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл | Factor vii chimeric molecules |
EP2529007B1 (en) | 2010-01-26 | 2017-07-12 | Anthrogenesis Corporation | Treatment of bone-related cancers using placental stem cells |
WO2012087241A1 (en) | 2010-12-20 | 2012-06-28 | Agency For Science, Technology And Research | Method of purifying exosomes |
US10139420B2 (en) | 2011-03-09 | 2018-11-27 | ISNERM (Institut National de la Sante et de la Recherche Medicale) | Methods for treating vaso-occlusive crisis using non-modified annexin V |
EP2734538B2 (en) * | 2011-07-18 | 2024-07-03 | IBA Lifesciences GmbH | Method of reversibly staining a target cell |
JP2015513913A (en) | 2012-04-02 | 2015-05-18 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | Modified polynucleotide |
TWI497845B (en) | 2012-07-18 | 2015-08-21 | Murata Manufacturing Co | Coaxial connector |
EP3184121A3 (en) | 2012-07-25 | 2017-09-27 | Salk Institute For Biological Studies | Lipid membranes with exposed phosphatidylserine as tam ligands, use for treating autoimmune diseases |
IL224860B (en) | 2012-09-19 | 2019-05-30 | Univ Georgetown | Methods for preparing targeted liposome complexes and uses thereof |
DK3524617T3 (en) | 2013-03-15 | 2023-05-15 | Gladiator Biosciences Inc | GLA DOMAINS AS THERAPEUTIC AGENTS |
EP3872090A1 (en) | 2014-03-11 | 2021-09-01 | Molecular Templates, Inc. | Proteins comprising amino-terminal proximal shiga toxin a subunit effector regions and cell-targeting immunoglobulin-type binding regions |
AU2015274647C1 (en) * | 2014-06-11 | 2020-01-30 | Molecular Templates, Inc. | Protease-cleavage resistant, Shiga toxin a subunit effector polypeptides and cell-targeted molecules comprising the same |
CN105457032A (en) | 2014-08-11 | 2016-04-06 | 中国人民解放军军事医学科学院毒物药物研究所 | Cancer stem cell-targeting carbon nano-tube-salinomycin drug delivery system, preparation method and uses thereof |
WO2017118764A1 (en) | 2016-01-07 | 2017-07-13 | Thomas Brocker | Novel approaches for the in vivo and in vitro visualization of dying cells |
CN105567642B (en) | 2016-02-01 | 2019-07-12 | 中国科学院生物物理研究所 | A kind of preparation method of xeroderma pitmentosum human pluripotent stem cells |
PE20201462A1 (en) | 2017-09-05 | 2020-12-17 | Gladiator Biosciences Inc | EXOSOME ADDRESSING METHOD |
-
2018
- 2018-09-05 PE PE2020000305A patent/PE20201462A1/en unknown
- 2018-09-05 WO PCT/US2018/049624 patent/WO2019051002A1/en active Search and Examination
- 2018-09-05 BR BR112020003945-4A patent/BR112020003945A2/en unknown
- 2018-09-05 CN CN201880057602.7A patent/CN111065733A/en active Pending
- 2018-09-05 CN CN201880056194.3A patent/CN111051500A/en active Pending
- 2018-09-05 JP JP2020512854A patent/JP2020533976A/en active Pending
- 2018-09-05 CA CA3074678A patent/CA3074678A1/en active Pending
- 2018-09-05 EP EP18789264.1A patent/EP3679129A1/en not_active Withdrawn
- 2018-09-05 JP JP2020534821A patent/JP2020533404A/en active Pending
- 2018-09-05 CA CA3074291A patent/CA3074291A1/en active Pending
- 2018-09-05 EP EP18779855.8A patent/EP3679128A1/en active Pending
- 2018-09-05 JP JP2020534820A patent/JP7365704B2/en active Active
- 2018-09-05 WO PCT/US2018/049619 patent/WO2019050998A1/en active Application Filing
- 2018-09-05 US US16/643,942 patent/US20200407421A1/en active Pending
- 2018-09-05 MX MX2020002250A patent/MX2020002250A/en unknown
- 2018-09-05 PE PE2020000281A patent/PE20201263A1/en unknown
- 2018-09-05 US US16/643,997 patent/US11981723B2/en active Active
- 2018-09-05 SG SG11202001536PA patent/SG11202001536PA/en unknown
- 2018-09-05 MX MX2020002442A patent/MX2020002442A/en unknown
- 2018-09-05 US US16/643,964 patent/US20200407422A1/en not_active Abandoned
- 2018-09-05 KR KR1020207007278A patent/KR20200050975A/en active IP Right Grant
- 2018-09-05 EP EP18779854.1A patent/EP3679127A1/en active Pending
- 2018-09-05 WO PCT/US2018/049618 patent/WO2019050997A1/en active Search and Examination
- 2018-09-05 AU AU2018330427A patent/AU2018330427A1/en not_active Abandoned
- 2018-09-05 BR BR112020004319-2A patent/BR112020004319A2/en unknown
- 2018-09-05 AU AU2018328223A patent/AU2018328223A1/en active Pending
- 2018-09-05 KR KR1020207005896A patent/KR20200050961A/en not_active Application Discontinuation
- 2018-09-05 SG SG11202001535RA patent/SG11202001535RA/en unknown
-
2020
- 2020-01-30 ZA ZA2020/00650A patent/ZA202000650B/en unknown
- 2020-02-18 ZA ZA2020/01012A patent/ZA202001012B/en unknown
- 2020-02-26 IL IL272908A patent/IL272908A/en unknown
- 2020-02-27 IL IL272942A patent/IL272942A/en unknown
-
2024
- 2024-03-18 JP JP2024041903A patent/JP2024073589A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL272942A (en) | Method of targeting exosomes | |
ZA202006746B (en) | Methods of treatment | |
HK1254287A1 (en) | Treatment of fibrosis | |
IL269409A (en) | Combinations of chk1- and wee1 - inhibitors | |
EP3684342C0 (en) | Method of treatment | |
GB201706406D0 (en) | Method of treatment | |
GB201904142D0 (en) | Improved method of FT-IMS | |
GB201502668D0 (en) | Method for isolation of polysaccharides | |
GB201815588D0 (en) | Method of treatment | |
GB201609170D0 (en) | Method of manufacture | |
GB2553390B (en) | Method of manufacture | |
GB201613971D0 (en) | Method of manufacture | |
GB201609171D0 (en) | Method of manufacture | |
GB2522904B (en) | Method of making an airdam | |
SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
GB201704816D0 (en) | Method of manufacture | |
GB201509048D0 (en) | Method of assembly | |
GB201513188D0 (en) | Method of tomography | |
GB201512139D0 (en) | Methods of treatment | |
GB2567222B (en) | Method of manufacture | |
PL3629754T3 (en) | Method of preparing adrosera | |
GB201721386D0 (en) | Chrondogy of time-wave | |
GB201704906D0 (en) | Method of manufacture | |
GB201720439D0 (en) | Method of treatment | |
GB201718589D0 (en) | Method of treatment |